Cardiomyocyte CaM kinase II as a driver of cardiac inflammation and remodeling

心肌细胞 CaM 激酶 II 作为心脏炎症和重塑的驱动因素

基本信息

  • 批准号:
    10308392
  • 负责人:
  • 金额:
    $ 39.5万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-12-15 至 2023-11-30
  • 项目状态:
    已结题

项目摘要

ABSTRACT The heart responds to stress through hypertrophic growth of cardiomyocytes and progresses to heart failure when stress is sustained. Our previous studies showed that hypertrophy in response to a variety of stimuli occurs independent of signaling through the calcium/calmodulin dependent protein kinase II (CaMKII) but that progression to heart failure is attenuated when CaMKII is deleted. Inflammation is a key contributor to the adverse remodeling associated with heart failure. The long term objective of this proposal is to demonstrate that CaMKII signaling within cardiomyocytes initiates cardiac inflammation in response to non-ischemic interventions such as pressure overload (TAC) and that this plays a significant role in the development of heart failure. Studies proposed in Aim 1 determine if cardiomyocyte localized CaMKII signaling drives cardiac inflammation using cardiac specific CaMKII knockout mice (CKO) to demonstrate loss of TAC-induced inflammatory gene expression and inflammasome activation. We determine if these responses occur specifically in cardiomyocytes by isolation of adult mouse ventricular myocytes from CTL and CKO mice, and by in situ hybridization and enzymatic assays in tissue sections. CaMKIIC transgenics and mice with cardiac specific KO of the p65 subunit of NFkB are used to further demonstrate involvement of the cardiomyocyte in igniting inflammation. Aim 2 asks whether cardiomyocyte CaMKII signaling contributes to accumulation of inflammatory/immune cells in response to TAC. Work in this aim uses CKO mice to demonstrate that TAC promotes immune cell responses through cardiomyocyte CaMKII initiated signals. Studies focus on macrophages and T-cells, using immunohistochemistry and flow cytometry as well as single cell RNA seq to comprehensively define specific populations of macrophages that accumulate in the heart. Cardiac specific KOs or knockdown of chemokines/cytokines is used to demonstrate that generation of these mediators in cardiomyocytes triggers responses of specific immune cell types. Aim 3 determines if blockade of cardiomyocyte CaMKII-initiated inflammation attenuates adverse remodeling and at what point this needs to be accomplished. Proposed studies use cardiac specific KO or inhibition of selected inflammatory mediators to demonstrate that their formation in cardiomyocytes is critical for development of fibrosis and ventricular dysfunction following TAC. Conditional gene deletion with AAV9 Cre is used to establish the time at which maximal benefit from CaMKII inhibition is achieved. Our findings should significantly impact future research since the cardiomyocyte has not previously been considered as a generator of inflammatory signals, the mechanisms by which inflammatory responses are activated in the absence of “alarmins” has not heretofore been determined, and the concept that most effective prevention of heart failure development could be achieved by early cardiomyocyte-targeted anti-inflammatory interventions is novel.
摘要 心脏通过心肌细胞的肥大生长对应激作出反应,并发展为心力衰竭 当压力持续时。我们以前的研究表明,肥大反应于各种刺激, 不依赖于通过钙/钙调蛋白依赖性蛋白激酶II(CaMKII)的信号传导, 当CaMKII缺失时,心力衰竭的进展减弱。炎症是一个关键因素, 与心力衰竭相关的不良重塑。这项建议的长远目标是 证明心肌细胞内的CaMKII信号传导启动心脏炎症反应, 非缺血性干预,如压力超负荷(TAC),这在 心力衰竭的发展。目标1中提出的研究确定心肌细胞是否定位于CaMKII 使用心脏特异性CaMKII敲除小鼠(CKO), TAC诱导的炎性基因表达和炎性小体活化的丧失。我们确定这些 通过从CTL中分离成年小鼠心室肌细胞, CKO小鼠,并通过原位杂交和组织切片中的酶测定。CaMKII β C转基因和 使用具有NFkB的p65亚基的心脏特异性KO的小鼠来进一步证明NFkB的p65亚基的参与。 心肌细胞引发炎症。目的2询问心肌细胞CaMKII信号传导是否有助于 炎症/免疫细胞响应于TAC的积聚。这项工作使用CKO小鼠, 证明TAC通过心肌细胞CaMKII启动的信号促进免疫细胞应答。 研究集中在巨噬细胞和T细胞,使用免疫组织化学和流式细胞术以及单克隆抗体。 cell RNA seq来全面定义在心脏中积聚的巨噬细胞的特定群体。 心脏特异性科斯或趋化因子/细胞因子的敲低用于证明这些细胞因子的产生 心肌细胞中的介质触发特定免疫细胞类型的应答。目标3确定是否封锁 心肌细胞CaMKII启动的炎症减弱了不良重塑, 需要完成。拟定的研究使用心脏特异性KO或抑制选定的炎性 介质,以证明它们在心肌细胞中的形成对纤维化的发展至关重要, TAC后的心室功能障碍。使用AAV 9 Cre的条件性基因缺失来确定在第一阶段的时间。 从而获得CaMKII抑制的最大益处。我们的发现将对未来产生重大影响。 研究由于心肌细胞以前没有被认为是炎症信号的发生器, 在缺乏“警报素”的情况下,炎症反应被激活的机制没有 迄今为止已经确定,最有效的预防心力衰竭发展的概念可以 通过早期心肌细胞靶向抗炎干预来实现是新颖的。

项目成果

期刊论文数量(14)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Molecular Signaling to Preserve Mitochondrial Integrity against Ischemic Stress in the Heart: Rescue or Remove Mitochondria in Danger.
  • DOI:
    10.3390/cells10123330
  • 发表时间:
    2021-11-27
  • 期刊:
  • 影响因子:
    6
  • 作者:
    Yu JD;Miyamoto S
  • 通讯作者:
    Miyamoto S
SiglecF(HI) Marks Late-Stage Neutrophils of the Infarcted Heart: A Single-Cell Transcriptomic Analysis of Neutrophil Diversification.
  • DOI:
    10.1161/jaha.120.019019
  • 发表时间:
    2021-02-16
  • 期刊:
  • 影响因子:
    5.4
  • 作者:
    Calcagno DM;Zhang C;Toomu A;Huang K;Ninh VK;Miyamoto S;Aguirre AD;Fu Z;Heller Brown J;King KR
  • 通讯作者:
    King KR
RhoA signaling increases mitophagy and protects cardiomyocytes against ischemia by stabilizing PINK1 protein and recruiting Parkin to mitochondria.
  • DOI:
    10.1038/s41418-022-01032-w
  • 发表时间:
    2022-12
  • 期刊:
  • 影响因子:
    12.4
  • 作者:
    Tu, MichelleZ;Tan, Valerie P.;Yu, Justin D.;Tripathi, Raghav;Bigham, Zahna;Barlow, Melissa;Smith, Jeffrey M.;Brown, Joan Heller;Miyamoto, Shigeki
  • 通讯作者:
    Miyamoto, Shigeki
The contribution of the cardiomyocyte to tissue inflammation in cardiomyopathies.
  • DOI:
    10.1016/j.cophys.2020.10.003
  • 发表时间:
    2021-03
  • 期刊:
  • 影响因子:
    2.5
  • 作者:
    Ninh VK;Brown JH
  • 通讯作者:
    Brown JH
A Kinase Interacting Protein 1 (AKIP1) promotes cardiomyocyte elongation and physiological cardiac remodelling.
  • DOI:
    10.1038/s41598-023-30514-1
  • 发表时间:
    2023-03-10
  • 期刊:
  • 影响因子:
    4.6
  • 作者:
    Nijholt, Kirsten T.;Sanchez-Aguilera, Pablo I.;Booij, Harmen G.;Oberdorf-Maass, Silke U.;Dokter, Martin M.;Wolters, Anouk H. G.;Giepmans, Ben N. G.;van Gilst, Wiek H.;Brown, Joan H.;de Boer, Rudolf A.;Sillje, Herman H. W.;Westenbrink, B. Daan
  • 通讯作者:
    Westenbrink, B. Daan
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JOAN HELLER BROWN其他文献

JOAN HELLER BROWN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JOAN HELLER BROWN', 18)}}的其他基金

RhoA and GPCR mediated transcriptional activation regulates glioblastoma
RhoA 和 GPCR 介导的转录激活调节胶质母细胞瘤
  • 批准号:
    9905280
  • 财政年份:
    2018
  • 资助金额:
    $ 39.5万
  • 项目类别:
RhoA and GPCR mediated transcriptional activation regulates glioblastoma
RhoA 和 GPCR 介导的转录激活调节胶质母细胞瘤
  • 批准号:
    10356023
  • 财政年份:
    2018
  • 资助金额:
    $ 39.5万
  • 项目类别:
Molecular Mechanism and Therapy for Ocular Melanoma
眼部黑色素瘤的分子机制及治疗
  • 批准号:
    10341047
  • 财政年份:
    2017
  • 资助金额:
    $ 39.5万
  • 项目类别:
Molecular Mechanism and Therapy for Ocular Melanoma
眼部黑色素瘤的分子机制及治疗
  • 批准号:
    10018829
  • 财政年份:
    2017
  • 资助金额:
    $ 39.5万
  • 项目类别:
ISHR 2013 World Congress
ISHR 2013 世界大会
  • 批准号:
    8597882
  • 财政年份:
    2013
  • 资助金额:
    $ 39.5万
  • 项目类别:
2010 Cardiac Regulatory Mechanisms Gordon Research Conference
2010年心脏调节机制戈登研究会议
  • 批准号:
    7905509
  • 财政年份:
    2010
  • 资助金额:
    $ 39.5万
  • 项目类别:
Restoration of Myocardial Healing through G-coupled Protein Receptor Signaling
通过 G 偶联蛋白受体信号转导恢复心肌愈合
  • 批准号:
    8452816
  • 财政年份:
    2006
  • 资助金额:
    $ 39.5万
  • 项目类别:
Cell Biology and Histology
细胞生物学和组织学
  • 批准号:
    8734480
  • 财政年份:
    2006
  • 资助金额:
    $ 39.5万
  • 项目类别:
Restoration of Myocardial Healing through G-coupled Protein Receptor Signaling
通过 G 偶联蛋白受体信号转导恢复心肌愈合
  • 批准号:
    8734475
  • 财政年份:
    2006
  • 资助金额:
    $ 39.5万
  • 项目类别:
Restoration of Myocardial Healing through G-coupled Protein Receptor Signaling
通过 G 偶联蛋白受体信号传导恢复心肌愈合
  • 批准号:
    9324068
  • 财政年份:
    2006
  • 资助金额:
    $ 39.5万
  • 项目类别:

相似海外基金

Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
  • 批准号:
    10727507
  • 财政年份:
    2023
  • 资助金额:
    $ 39.5万
  • 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
  • 批准号:
    9194162
  • 财政年份:
    2016
  • 资助金额:
    $ 39.5万
  • 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
  • 批准号:
    496858-2016
  • 财政年份:
    2016
  • 资助金额:
    $ 39.5万
  • 项目类别:
    University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
  • 批准号:
    9201955
  • 财政年份:
    2015
  • 资助金额:
    $ 39.5万
  • 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
  • 批准号:
    8251289
  • 财政年份:
    2014
  • 资助金额:
    $ 39.5万
  • 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
  • 批准号:
    8302750
  • 财政年份:
    2012
  • 资助金额:
    $ 39.5万
  • 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
  • 批准号:
    267940
  • 财政年份:
    2012
  • 资助金额:
    $ 39.5万
  • 项目类别:
    Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
  • 批准号:
    8403458
  • 财政年份:
    2012
  • 资助金额:
    $ 39.5万
  • 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
  • 批准号:
    8549297
  • 财政年份:
    2012
  • 资助金额:
    $ 39.5万
  • 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
  • 批准号:
    8472443
  • 财政年份:
    2012
  • 资助金额:
    $ 39.5万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了